Last week, On The Pen reported that Eli Lilly was working with the FDA to provide retatrutide through the agency’s expanded access, or compassionate use, pathway. This week, it happened.

According to STAT, a 79-year-old man has become the first known patient to receive retatrutide outside of a clinical trial.

The news is significant not because it changes…